Clinical trial
Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2…
NCT00085969 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00085969 |
|---|---|
| Title | Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus |
| Official title | A Phase 2, Randomized, Triple-Blind, Placebo-Controlled, Multicenter Study to Examine the Effect of Exenatide Monotherapy on Glucose Control in Subjects With Type 2 Diabetes Mellitus |
| Lead sponsor | AstraZeneca, Industry |
| Collaborators | Eli Lilly and Company Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | Placebo 0.04 mL twice daily, Placebo 0.04 mL once daily, Placebo 0.08 mL once daily, B - Exenatide 10 mcg twice daily, C - Exenatide 10 mcg once daily, Exenatide 20 mcg once daily |
| Enrollment | 99 |
| Start date | Sep 1, 2003 |
| Primary completion | Jan 1, 2004 |
| Completion | Jan 1, 2004 |
| First posted | Jun 22, 2004 |
| Last update posted | Feb 23, 2015 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: